BCAB

BioAtla (BCAB)

About BioAtla (BCAB)

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Details

Daily high

$0.17

Daily low

$0.15

Price at open

52 Week High

$1.43

52 Week Low

$0.13

Market cap

11.0M

Dividend yield

0.00%

Volume

2,605

Avg. volume

1.6M

P/E ratio

-.13

BioAtla News